Diabetes, inflammation, proinflammatory cytokines, and diabetic nephropathy

TheScientificWorldJournal

Volumn 6, Issue , 2006, Pages 908-917

  Navarro, Juan F ^a,b   Mora, Carmen ^a,b  

^a HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

^b CSIC   (Spain)

Author keywords

Diabetes; Diabetic nephropathy; Inflammation; Proinflammatory cytokines

Indexed keywords

CYTOKINE;

DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE COURSE; HUMAN; IMMUNOSTIMULATION; INFLAMMATION; INNATE IMMUNITY; KIDNEY FAILURE; KIDNEY INJURY; MICROANGIOPATHY; NONHUMAN; PATHOGENESIS; PUBLIC HEALTH; REVIEW;

ANIMALS; CYTOKINES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33747385291     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1100/tsw.2006.179     Document Type: Review

References (102)

1. Vivian, E.M. (2006) Type 2 diabetes in children and adolescents - the next epidemic? Curr. Med. Res. Opin. 22, 297-306.
2. Ritz, E., Rychlik, I., Locatelli, F., and Halimi, S. (1999) End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions. Am. J. Kidney Dis. 34, 795-808.
3. Pickup, J. and Crook, M. (1998) Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 41, 1241-1248.
4. Festa, A., D'Agostino, R., Howard, G., Mykkänen, L., Tracy, R.P., and Haffner, S.M. (2000) Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 101, 42-47.
5. Ford, E.S. (1999) Body mass index, diabetes, and C-reactive protein among US adults. Diabetes 22, 1971-1977.
6. Müller, S., Martin, S., Koenig, W., Hanifi-Moghaddam, P., Rathmann, W., Haastert, B., Giani, G., Illig, T., Thorand, B., and Kolb, H. (2002) Impaired glucose tolerance is associated with increased serum concentrations of interleukin 6 and co-regulated acute-phase proteins but not TNF-α or its receptors. Diabetologia 45, 805-812.
7. Temelkova-Kurktschiev, T., Henkel, E., Koelher, C., Karrei, K., and Hanefield, M. (2002) Subclinical inflammation in newly detected type II diabetes and impaired glucose tolerance. Diabetologia 45, 151
8. Rodríguez-Morán, M. and Guerrero-Romero, F. (1999) Increased levels of C-reactive protein in noncontrolled type II diabetic subjects. J. Diabetes Complications 13, 211-215.
9. Leinonen, E., Hurt-Camejo, E., Wiklund, O., Hultén, L.M., Hiukka, A., and Taskinen, R.M. (2001) Insulin resistance and adiposity correlate with acute-phase reaction and soluble cell adhesion molecules in type 2 diabetes. Atherosclerosis 166, 387-394.
10. Navarro, J.F., Mora, C., Macía, M., and García, J. (2003) Inflammatory parameters are independently associated with urinary albumin excretion in type 2 diabetes mellitus. Am. J. Kidney Dis. 42, 53-61.
11. Katsuki, A., Sumida, Y., Murashima, S., Murata, K., Takarada, Y., Ito, K., Fujii, M., Tsuchihashi, K., Goto, H., and Nakatani, K. (1998) Serum levels of tumor necrosis factor-alpha are increased in obese patients with noninsulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 83, 859-862.
12. Pickup, J.C., Chusney, G.C., Thomas, S.M., and Burt, D. (2000) Plasma interleukin-6, tumor necrosis factor alpha and blood cytokine production in type 2 diabetes. Life Sci. 67, 291-300.
13. Schmidt, M.I., Duncan, B.B., Sharrett, A.R., Lindberg, G., Savage, P.J., Offenbacher, S., Azambuja, M.I., Tracey, R.P., and Heiss, G. (1999) Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet 353, 1649-1652.
14. Duncan, B.B., Schmidt, M.I., Offenbacher, S., Wu, K.K., Savage, P.J., and Heiss, G. (1999) Factor VIII and other hemostasis variables are related to incident diabetes in adults: the Atherosclerosis Risk in Communities (ARIC) study. Diabetes Care 22, 767-772.
15. Pradhan, A.D., Manson, J.E., Rifai, N., Buring, J.E., and Ridker, P.M. (2001) C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286, 327-334.
16. Festa, A., D'Agostino, R., Tracey, R.P., and Haffner, S.M. (2002) Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the Insulin Resistance Atherosclerosis Study. Diabetes 51, 1131-1137.
17. Spranger, J., Kroke, A., Möhlig, M., Hoffman, K., Bergman, M.M., Ristow, M., Boeing, H., and Pfeiffer, A.F.H. (2003) Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC) Postsdam study. Diabetes 52, 812-817.
18. Yuan, M., Konstantopoulos, N., Lee, J., Hansen, L., Li, Z.W., Karim, M., and Shoelson, S.E. (2001) Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 293, 1673-1677.
19. Freeman, D.J., Norrie, J., Naveed, S., Neely, D.G., Cobbe, S.M., Ford, I., Isles, C., Lorimer, A.R., Macfarlane, P.W., McKillop, J.H., Packard, C.J., Shepherd, J., and Gaw, A. (2001) Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 103, 357-362.
20. Weitz-Schmidt, G. (2002) Statins as anti-inflammatory agents. Trends Pharmacol. Sci. 23, 482-486.
21. McFarlane, S.I., Muniyappa, R., Francisco, R., and Stowers, J.R. (2002) Pleiotropic effects of statins: lipid reduction and beyond. J. Clin. Endocrinol. Metab. 87, 1451-1458.
22. Levin, K., Hother-Nielsen, O., Henriksen, J.E., and Beck-Nielsen, H. (2004) Effects of troglitazone in young first-degree relatives of patients with type 2 diabetes. Diabetes Care 2, 148-154.
23. Anderson, D.C., Jr. (2005) Pharmacologic prevention or delay of type 2 diabetes mellitus. Ann. Pharmacother. 39, 102-109.
24. Ricote, M., Li, A.C., Wilson, T.M., Kelly, C.J., and Glass, C.K. (1998) The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 391, 79-82.
25. Jiang, C., Ting, A.T., and Seed, B. (1998) PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 391, 82-85.
26. Haffner, S.M., Greenberg, A.S., Weston, W.M., Chen, H., Williams, K., and Freed, M.I. (2002) Effect of rosiglitazone treatment on non-traditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 106, 679-684.
27. Crook, M. (2004) Type 2 diabetes mellitus: a disease of the innate immune system? An update. Diabet. Med. 21, 203-207.
28. Tanaka, T., Itoh, H., Doi, K., Fukunaga, K., Shintani, M., Yamashita, J., Chun, T.H., Inoue, M., Masatsugu, K., Sawada, N., Saito, T., Nishimura, H., Yoshimasa, Y., and Nakao, K. (1999) Downregulation of peroxisome proliferators-activated receptor γ expression by inflammatory cytokines and its reversal by thiazolidinediones. Diabetologia 42, 702-710.
29. Boden, G. (2004) Free fatty acids as target for therapy. Curr. Opin. Endocrinol. Diab. 11, 258-263.
30. Itani, S., Ruderman, N., Schmieder, S., and Boden, G. (2002) Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IκB-α. Diabetes 51, 2005-2011.
31. Samuel, V., Liu, Z., Qu, X., Elder, B., Bilz, S., Befroy, D., Romanelli, A., and Shulman, G. (2004) Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J. Biol. Chem. 279, 32345-32353.
32. Boden, G. and Chen, X. (1995) Effects of fat on glucose uptake and utilization in patients with non-insulin-dependent diabetes. J. Clin. Invest. 96, 1261-1268.
33. Dresner, A., Laurent, D., Marcucci, M., Griffin, M.E., Dufour, S., Cline, G., Slezak, L., Andersen, D., Hundal, R., Rothman, D., Petersen, K., and Shuman, G. (1999) Effects of fatty acids on glucose transport and IRS-1 associated phosphatidylinositol 3-kinase activity. J. Clin. Invest. 103, 253-259.
34. Boden, G., She, P., Mozzoli, M., Cheung, P., Gumireddy, K., Reddy, P., Xiang, X., Luo, Z., and Ruderman, N. (2005) Free fatty acids produce insulin resistance and activate the proinflammatory nuclear factor-κB pathway in rat liver. Diabetes 54, 3458-3465.
35. De Alvaro, C., Teruel, T., Hernández, R., and Lorenzo, M. (2004) Tumor necrosis factor α produces insulin resistance in skeletal muscle by activation of inhibitor κB kinase in a p38 MAPK-dependent manner. J. Biol. Chem. 279, 17070-17078.
36. Stephens, J. and Pekala, P. (1992) Transcriptional repression of C/EBP and GLUT4 genes in the 3T3-L1 adipocytes by tumor necrosis factor-α: regulation is coordinate and independent of protein synthesis. J. Biol. Chem. 267, 13580-13584.
37. Stephens, J., Lee, J., and Pilch, P. (1997) Tumor necrosis factor-α induced insulin resistance in 3T3-L1 adipocytes is accompanied by a loss of insulin receptor substrate-1 and GLUT4 expression without a loss of insulin receptor mediated signal transduction. J. Biol. Chem. 272, 971-976.
38. Starr, R., Willson, T.A., Viney, E., Murray, L., Rayner, J., Jenkins, B., Gonda, T., Alexander, W., Metcalf, D., Nicola, N., and Hilton, D. (1997) A family of cytokine-inducible inhibitors of signalling. Nature 387, 917-921.
39. Krebs, D. and Hilton, D. (2000) SOCS: physiological suppressors of cytokine signalling. J. Cell Sci. 113, 2813-2819.
40. Mooney, R., Senn, J., Cameron, S., Inamdar, N., Boivin, L., Shag, Y., and Furlanetto, R. (2001) Suppressors of cytokine signialing-1 and -6 associate with and inhibit the insulin receptor. J. Biol. Chem. 276, 25889-25893.
41. Day, C.P., Grove, J., Daly, A.K., Stewart, M.W., Avery, P.J., and Walker, M. (1998) Tumor necrosis factor alpha gene promoter polymorphism and decreased insulin resistance. Diabetologia 41, 430-434.
42. Fernández-Real, J., Vendrell, J., Ricart, W., Broach, M., Gutiérrez, C., Casamitjana, R., Oriola, J., and Richard, C. (2000) Interleukin-6 gene polymorphism and insulin sensitivity. Diabetes 49, 517-520.
43. Dalla Vestra, M., Mussap, M., Gallina, P., Bruseghin, M., Cernigoi, A.M., Saller, A., Plebani, M., and Fioretto, P. (2005) Acute-phase markers of inflammation and glomerular structure in patients with type 2 diabetes. J. Am. Soc. Nephrol. 16, S78-S82.
44. Chow, F.Y., Nikolic-Paterson, D.J., Ozols, E., Atkins, R.C., and Tesch, G.H. (2005) Intracellular adhesion molecule-1 deficiency is protective against nephropathy in type 2 diabetic db/db mice. J. Am. Soc. Nephrol. 16, 1711-1722.
45. Kelly, D.J., Chanty, A., Gow, R.M., Zhang, Y., and Gilbert, R.E. (2005) Protein kinase C beta inhibition attenuates osteopontin expression, macrophage recruitment, and tubulointerstitial injury in advanced experimental nephropathy. J. Am. Soc. Nephrol. 16, 1654-1660.
46. Shanmugam, N., Reddy, M.A., Guha, M., and Natarajan, R. (2003) High glucose-induced expression of proinflammatory cytokine and chemokine genes in monocytic cells. Diabetes 52, 1256-1264.
47. Banba, N., Nakamura, T., et al. (2000) Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy. Kidney Int. 58, 684-690.
48. Hasegawa, G., Nakano, K., Sawada, M., Sawada, M., Uno, K., Shibayama, Y., Ienaga, K., and Kondo, M. (1991) Possible role of tumor necrosis factor and interleukin-1 in the development of diabetic nephropathy. Kidney Int. 40, 1007-1012.
49. Royall, J.A., Berkow, R.L., Beckman, J.S., Cunningham, M.K., Matalon, S., and Freeman, B.A. (1989) Tumor necrosis factor and interleukin 1 increase vascular endothelial permeability. Am. J. Physiol. 257, L339-L410.
50. Melcion, C., Lachman, L., Killen, D., Morel-Maroger, L., and Striker, G.E. (1982) Mesangial cells, effect of monocyte products on proliferation, and matrix synthesis. Transplant. Proc. 14, 559-564.
51. Pfeilschfer, J., Pignat, W., Vosbeck, K., and Märki, F. (1989) Interleukin 1 and tumor necrosis factor synergistically stimulate prostaglandin synthesis and phospholipase A2 release from rat renal mesangial cells. Biochem. Biophys. Res. Commun. 159, 385-394.
52. Hirano, T., Akira, S., Taga, T., and Kishimoto, T. (1990) Biological and clinical aspect of interleukin 6. Immunol. Today 11, 443-449.
53. Baud, L. and Ardaillou, R. (1995) Tumor necrosis factor in renal injury. Miner. Electrolyte Metab. 21, 336-341.
54. Noronha, I.L., Niemir, Z., Stein, H., and Waldherr, R. (1995) Cytokines and growth factors in renal disease. Nephrol. Dial. Transplant. 10, 775-786.
55. Hasegawa, G., Nakano, K., and Kondo, M. (1995) Role of TNF and IL-1 in the development of diabetic nephropathy. Nefrologia 15, 1-4.
56. Nakamura, T., Fukui, M., Ebihara, I., Osada, S., Nagaoka, I., Tomino, Y., and Koide, H. (1993) mRNA expression of growth factors in glomeruli of diabetic rats. Diabetes 42, 450-456.
57. Sugimoto, H., Shikata, K., Wada, J., Horiuchi, S., and Makino, H. (1999) Advanced glycation end products-cytokine-nitric oxide sequence pathway in the development of diabetic nephropathy: aminoguanidine ameliorates the overexpression of tumour necrosis factor-α and inducible nitric oxide synthase in diabetic rat glomeruli. Diabetologia 42, 878-886.
58. Navarro, J., Milena, F., Mora, C., León, C., Claveríe, F., Flores, C., and García, J. (2005) Tumor necrosis factor-α gene expression in diabetic nephropathy: relationship with urinary albumin excretion and effect of angiotensin-converting enzyme inhibition. Kidney Int. 68(Suppl 99), S98-S102.
59. Baud, L., Pérez, J., Friedlander, G., and Ardaillou, R. (1988) Tumor necrosis factor stimulates prostaglandin production and cyclic AMP levels in rat cultured mesangial cells. FEBS Lett. 239, 50-54.
60. Ortiz, A., González-Cuadrado, S., Bustos, C., Alonso, J., Gómez-Guerrero, C., López-Armada, M.J., González, E., Plaza, J.J., and Egido, J. (1995) Tumor necrosis factor as a mediator of glomerular damage. J. Nephrol. 8, 27-34.
61. Bertani, T., Abbate, M., Zoja, C., Corna, D., Perico, N., Ghezzi, P., and Remuzzi, G. (1989) Tumor necrosis factor induces glomerular damage in rabbit. Am. J. Pathol. 134, 419-430.
62. MaCarthy, E., Sharma, R., Sharma, M., Li, J.Z.; Ge, X.L., Dileepan, K.N., and Savin, V.J. (1998) TNF-α increases albumin permeability of isolated rat glomeruli through the generation of superoxide. J. Am. Soc. Nephrol. 9, 433-438.
63. Kalantarinia, K., Awas, A.S., and Siragy, H.M. (2003) Urinary and renal interstitial concentrations of TNF-α increase prior to the rise in albuminuria in diabetic rats. Kidney Int. 64, 1208-1213.
64. Schmouder, R.L., Strieter, R.M., Wiggins, R.C., Chensue, S.W., and Kunkel, S.L. (1992) In vitro and in vivo interleukin-8 production in human renal cortical epithelia. Kidney Int. 41, 191-198.
65. Ishikura, H., Takahashi, C., Kanagawa, K., Hirata, H., Imai, K., and Yoshiki, T. (1991) Cytokine regulation of ICAM-1 expression on human renal tubular epithelial cells in vitro. Transplantation 51, 1272-1275.
66. Chow, F.Y., Nikolic-Paterson, D.J., Ozols, E., Atkins, R.C., and Tesch, G.H. (2005) Intercellular adhesion molecule-1 deficiency is protective against nephropathy in type 2 diabetic db/db mice. J. Am. Soc. Nephrol. 16, 1711-1722.
67. Schreiner, G.F. and Kohan, D.E. (1990) Regulation of renal transport processes and hemodynamics by macrophages and lymphocytes. Am. J. Physiol. 258, F761-F767.
68. Dipetrillo, K., Coutermarsh, B., and Gesek, F.A. (2003) Urinary tumor necrosis factor contributes to sodium retention and renal hypertrophy during diabetes. Am. J. Physiol. Renal Physiol. 284, F113-F121.
69. Navarro, J.F., Mora, C., Rivero, A., Gallego, E., Chahin, J., Macia, M., Mendez, M.L., and Garcia, J. (1999) Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: effects of pentoxifylline administration. Am. J. Kidney Dis. 33, 458-463.
70. The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329, 977-986.
71. United Kingdom Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352, 837-853.
72. Lewis, E.J., Hunsicker, L.G., Bain, R.P., and Rohde, R.D. (1993) The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N. Engl. J. Med. 329, 1456-1462.
73. Brenner, B.M., Cooper, M.E., de Zeeuw, D., Keane, W.F., Mitch, W.E., Parving, H.H., Remuzzi, G., Snapinn, S.M., Zhang, Z., and Shahinfar, S. (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 345, 861-869.
74. Lewis, E.J., Hunsicker, L.G., Clarke, W.R., Berl, T., Pohl, M.A., Lewis, J.B., Ritz, E., Atkins, R.C., Rohde, R., and Raz, I. (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 345, 851-860.
75. Ruggenenti, P., Fassi, A., Ilieva, A.P., Bruno, S., Iliev, I.P., Brusegan, V., Rubis, N., Gherardi, G., Arnoldi, F., Ganeva, M., Ene-Iordache, B., Gaspari, F., Perna, A., Bossi, A., Trevisan, R., Dodesini, A.R., Remuzzi, G.; Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators (2004) Preventing microalbuminuria in type 2 diabetes. N. Engl. J. Med. 351, 1941-1951.
76. Hostetter, T.H. (2001) Prevention of end-stage renal disease due to type 2 diabetes. N. Engl. J. Med. 345, 910-912.
77. Cheng, H.F., Wang, C.J., Moeckel, G.W., Zhang, M.Z., McKanna, J.A., and Harris, R.C. (2002) Cyclooxygenase-2 inhibitor blocks expression of mediators of renal injury in a model of diabetes and hypertension. Kidney Int. 62, 929-939.
78. Utimura, R., Fujihara, C.K., Mattar, A.L., Malheiros, D.M., Noronha, I.L., and Zatz, R. (2003) Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes. Kidney Int. 63, 209-216.
79. Kikuchi, Y., Imakiire, T., Yamada, M., Saigusa, T., Hyodo, T., Hyodo, N., Suzuki, S., and Miura, S. (2005) Mizoribine reduces renal injury and macrophage infiltration in non-insulin-dependent diabetic rats. Nephrol. Dial. Transplant. 20, 1573-1581.
80. Epstein, M. (2001) Aldosterone as a determinant of cardiovascular and renal dysfunction. J. R. Soc. Med. 94, 378-383.
81. Epstein, M. (2001) Aldosterone as a mediator of progressive renal disease: pathogenic and clinical implications. Am. J. Kidney Dis. 37, 677-688.
82. Rossing, K., Schjoedt, K., Smidt, U., Boomsma, R., and Parving, H.H. (2005) Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy. Diabetes Care 28, 2106-2112.
83. Han, S.Y., Kim, C.H., Kim, H.S., Jee, Y.H., Song, H.K., Lee, H.K., Han, K.H., Kim, H.K., Kang, Y.S., Han, Y.S., Kim, Y.S., and Cha, D.R. (2006) Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. J. Am. Soc. Nephrol. 17, 1362-1372.
84. Takebayashi, K., Matsumoto, S., Aso, Y., and Inukai, T. (2006) Aldosterone blockade attenuates urinary chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy. J. Clin. Endocrinol. Metab., in press.
85. Xia, P., Inoguchi, T., Kern, T.S., Engerman, R.L., Oates, P.J., and King, G.L. (1994) Characterization of the mechanism for the chronic activation of diacylglycerol-protein kinase C pathway in diabetes and hypergalactosemia. Diabetes 43, 1122-1129.
86. Tuttle, K.R. and Anderson, P.W. (2003) A novel potential therapy for diabetic nephropathy and vascular complications: protein kinase C beta inhibition. Am. J. Kidney Dis. 42, 456-465.
87. Tuttle, K.R., Bakris, G.L., Toto, R.D., McGill, J.B., Hu, K., and Anderson, P.W. (2005) The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care 28, 2686-2690.
88. Han, J., Thompson, P., and Beutler, D. (1990) Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signalling pathway. J. Exp. Med. 172, 393-394.
89. Doherty, G.M., Jensen, J.C., Alexander, H.R., Buresh, C.M., and Norton, J.A. (1991) Pentoxifylline suppression of tumor necrosis factor gene transcription. Surgery 110, 192-198.
90. Segal, R., Dayan, M., Zinger, H., and Mozes, E. (2001) Suppression of experimental systemic lupus erythematosus (SLE) in mice via TNF inhibition by an anti-TNFα monoclonal antibody and by pentoxifillyne. Lupus 10, 23-31.
91. Chen, Y.M., Ng, Y.Y., Lin, S.L., Chiang, W.C., Lan, H.Y., and Tsai, T.J. (2004) Pentoxifylline suppresses renal tumour necrosis factor-α and ameliorates experimental crescentic glomerulonephritis in rats. Nephrol. Dial. Transplant. 19, 1106-1115.
92. Chen, Y.M., Chien, C.T., Hu-Tsai, M.I., Wu, K.D., Tsai, C.C., Wu, M.S., and Tsai, T.J. (1999) Pentoxifylline attenuates experimental mesangial proliferative glomerulonephritis. Kidney Int. 56, 932-943.
93. Lin, S.L., Chen, Y.M., Chien, C.T., Chiang, W.C., Tsai, C.C., and Tsai, T.J. (2002) Pentoxifylline attenuated the renal disease progression in rats with remnant kidney. J. Am. Soc. Nephrol. 13, 2916-2929.
94. DiPetrillo, K. and Gesek, F.A. (2004) Pentoxifylline ameliorates renal tumor necrosis factor expression, sodium retention, and renal hypertrophy in diabetic rats. Am. J. Nephrol. 24, 352-359.
95. Guerrero-Romero, F., Rodríguez-Morán, M., Paniagua-Sierra, J., García-Bulnes, G., Salas-Ramírez, M., and Amato, D. (1995) Pentoxifylline reduces proteinuria in insulin-dependent and non-dependent diabetic patients. Clin. Nephrol. 43, 116-121.
96. Navarro, J., Mora, C., Muros, M., Macía, M., and García, J. (2003) Effects of pentoxifylline administration on urinary N-acetyl-beta- glucosaminidase excretion in type 2 diabetic patients: a short-term, prospective, randomised study. Am. J. Kidney Dis. 42, 264-270.
97. Harmankaya, O., Seber, S., and Yilmaz, M. (2003) Combination of pentoxifylline with angiotensin converting enzyme inhibitors produces an additional reduction in microalbuminuria in hypertensive type 2 diabetic patients. Ren. Fail. 25, 465-470.
98. Navarro, J.F., Mora, C., Muros, M., and García, J. (2005) Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomised, controlled trial. J. Am. Soc. Nephrol. 16, 2119-2126.
99. Chen, Y.M., Lin, S.L., Chiang, W.C., Wu, K.D., and Tsai, T.J. (2006) Pentoxifylline ameliorates proteinuria through suppression of renal monocyte chemoattractant protein-1 in patients with proteinuric primary glomerular diseases. Kidney Int. 69, 1410-1415.
100. Zimmet, P., Alberti, K.G., and Shaw, J. (2001) Global and societal implications of the diabetes epidemic. Nature 414, 782-787.
101. U.S. Renal Data System: USRDS 2004 Annual Data Report. In Atlas of End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD.
102. Tuttle, K.R. (2005) Linking metabolism and immunology: diabetic nephropathy is an inflammatory disease. J. Am. Soc. Nephrol. 16, 1537-1538.